Status:
TERMINATED
Soluble CD23 Expression in Asthma Patients Treated With OMA
Lead Sponsor:
University of Mississippi Medical Center
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Asthma
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergi...
Detailed Description
This is a 1 year placebo controlled study looking at moderate to severe asthmatics (allergic or non-allergic) who are controlled by medication. Skin testing will be done to determine the allergic sta...
Eligibility Criteria
Inclusion
- Moderate to severe asthmatic (based on 1997 NHLBI guidelines), controlled by medication for at least 6 months, initial IgE level between 30 and 700 IU, weigh between 30 an 150 kg, otherwise healthy.
Exclusion
- Smoker, uncontrolled asthma, immunotherapy in past six weeks, other diseases
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00226200
Start Date
November 1 2004
End Date
October 1 2007
Last Update
December 1 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216